Current standard of care combines cytogenetic results with testing for mutations in FLT3, NPM1, CEBPA, and KIT. The presence of FLT3 ITD, NPM1, or CEBPA mutations refines the prognosis of patient with AML with normal karyotype which is normally intermediate risk. Here, FLT3 is linked to acute myeloid leukemia.